Influenza mRNA Vaccines 2023

This article discusses the potential of utilizing mRNA technology, which has been popularized during the COVID-19 pandemic, to create safe and effective vaccines for the influenza virus. Traditional influenza vaccines offer varying levels of immunity and have limitations due to their egg-based production. The use of mRNA technology can overcome these limitations and improve efficacy and protection. The article also explores the regulatory process for non-COVID mRNA-based vaccines and the current development landscape for mRNA flu vaccines, including the use of platform technologies such as lipid nanoparticles. Additionally, the article highlights groundbreaking work from academics in the mRNA field, which offers broad protection through novel delivery methods. The potential for combined vaccines for COVID-19 and influenza is also discussed. Analytical and CMC considerations are explored to ensure the quality, safety, and efficacy of mRNA drugs, and efficient manufacturing processes are needed to meet the demand for influenza vaccinations. Ultimately, the use of mRNA technology for influenza vaccines has the potential to overcome the greatest risk to public health pre- and post-pandemic.